Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.49 |
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | LSS | P48449 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.40 |
| ▸ | CCND3 | P30281 | 2/20 | 0.38 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.38 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1610503 | 0.85 | TNKS (0.48) | TNKSCHRNB1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL14930382 | 0.81 | TNKS (0.39) | TNKSKCNH2CHRNB1CHRNB2CHRNB4 | |
| SCHEMBL12093737 | 0.81 | KDM4E (0.47) | TNKSCHRNB1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL18929477 | 0.81 | KDM4E (0.51) | TNKSCHRNB1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL24567826 | 0.81 | QDPR (0.47) | QDPRLSSTGFBR1ACVR1KCNH2 | |
| SCHEMBL13085544 | 0.81 | QDPR (0.47) | QDPRTLR9TLR8TLR7TNKS | |
| SCHEMBL1392852 | 0.81 | QDPR (0.47) | QDPRTNKSLSS | |
| SCHEMBL21037759 | 0.81 | CHRNB2 (0.53) | QDPRLSSCHRNB2CHRNA3CHRNA4 | |
| SCHEMBL31536280 | 0.81 | QDPR (0.47) | QDPRLSSTGFBR1ACVR1KCNH2 | |
| SCHEMBL11962323 | 0.79 | SMN1; SMN2 (0.54) | TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024054469-A1 | ISOQUINOLONES AS PI3K INHIBITORS | ONKURE, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20230234959-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2022236253-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022236256-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| EP-4050012-A1 | PYRIDONE BORONATES FOR THE PREPARATION OF INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-08-31 | — | — | EP | disclosed |
| EP-4019508-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-06-29 | — | — | EP | disclosed |
| EP-3204382-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-12-01 | — | — | EP | disclosed |
| EP-3521288-B1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | HOFFMANN LA ROCHE (CH) | 2021-09-08 | — | — | EP | disclosed |
| WO-2020141439-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-09 | — | — | WO | disclosed |
| EP-3521288-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2019-08-07 | — | — | EP | disclosed |
| US-20140378432-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH INC (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140194408-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8716274-B2 | Heteroaryl pyridone and aza-pyridone compounds | GENENTECH, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20140057896-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2014-02-27 | — | — | US | disclosed |
| US-20130261103-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GENENTECH, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| WO-2013067274-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | GENENTECH, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130116235-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2012030990-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20120010191-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2008007123-A2 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261103-A1 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, TYK2, LCK | QDPR 2442/4885TLR9 526/4885TLR8 491/4885 |
| US-20140057896-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | QDPR 1732/4885TLR9 705/4885TLR8 1003/4885 |
| US-20120010191-A1 | PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, BTK, LCK | QDPR 1732/4885TLR9 705/4885TLR8 1003/4885 |
| US-20130116235-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | BTK, PDXK, TYK2 | QDPR 2975/4885TLR9 878/4885TLR8 1507/4885 |
| US-20140378432-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | QDPR 1746/4885TLR9 956/4885TLR8 1082/4885 |
| US-20140194408-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | BTK, PDXK, TYK2 | QDPR 2975/4885TLR9 878/4885TLR8 1507/4885 |
| US-20230234959-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | SIK1, SIK2, SIK3 | QDPR 4720/4885TLR9 4860/4885TLR8 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.